Drug intelligence / Profile preview

NNC0471-0119 B

Development stage: Unknown
Lead developer: Novo Nordisk
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

NNC0471-0119 B is one of three formulations of NNC0471-0119, a new rapid-acting insulin analogue developed by Novo Nordisk A/S for the treatment of type 1 diabetes. It is designed for administration via an insulin pump as a bolus dose on top of a continuous basal rate. The drug is currently being investigated for its pharmacokinetic, pharmacodynamic, safety, and tolerability properties.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on NNC0471-0119 B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0471-0119 B.

Explore the full profile